mosunetuzumab
mosunetuzumab: 14 clinical trials tracked.
mosunetuzumab evidence translation
What we can confirm
14 tracked trials
What it means
What to watch
Prepared research question
What is verified about mosunetuzumab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 5 study sponsors
Related indications
Clinical Trials (14)showing 10 most recent
MOZART MZL: A Randomized Phase II Study Evaluating Mosunetuzumab Alone and in Combination With Either Zanubrutinib or Polatuzumab Vedotin for the Treatment of Patients With Relapsed/Refractory Marginal Zone Lymphoma
Primary endpoint: Complete response rate (arm 1 versus arm 2)
A Phase II Study of Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)
Primary endpoint: The recommended phase 2 dose (RP2D) which will be determined based on the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period.
A Prospective, Multicenter, Phase 2 Study of Mosunetuzumab in Combination With Zeprumetostat for the Treatment of Follicular Lymphoma
Primary endpoint: Best Complete Response (CR) Rate (Cohort 1 and Cohort 3)
PROMOTE-FL: Pirtobrutinib and Mosunetuzumab to Enhance Treatment Efficacy for Patients With Relapsed/Refractory Follicular Lymphoma
Primary endpoint: Complete remission (CR) rate
ctDNA-Guided Mosunetuzumab Consolidation Therapy in Older Patients With Untreated DLBCL
Primary endpoint: ctDNA clearance rate after mosunetuzumab treatment
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
Primary endpoint: Substudy 1 Part 1a: Number of participants with dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and serious adverse events
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Primary endpoint: 3-year milestone progression free survival (PFS)
A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular Lymphoma
Primary endpoint: Progression Free Survival (PFS)
NORM: Nodular Lymphocyte-Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase 2 Trial With Either Rituximab or Mosunetuzumab
Primary endpoint: Progression-free survival (PFS) time
A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Primary endpoint: Unacceptable toxicity (Safety Lead-in)